Finch Therapeutics Group, Inc. (FNCH)
USD 12.74
(-0.08%)
USD 12.74
(-0.08%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -7.09 Million USD | 69.59% |
| 2022 | -4.64 Million USD | 88.01% |
| 2021 | -38.74 Million USD | -52.4% |
| 2020 | -25.42 Million USD | -358.38% |
| 2019 | 9.84 Million USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | - USD | 100.0% |
| 2024 Q1 | -43 Thousand USD | -101.54% |
| 2023 Q3 | -52 Thousand USD | 8.77% |
| 2023 FY | -1.41 Million USD | 69.59% |
| 2023 Q4 | 2.8 Million USD | 5486.54% |
| 2023 Q2 | -57 Thousand USD | 95.48% |
| 2023 Q1 | -1.26 Million USD | 10.0% |
| 2022 Q2 | -13.56 Million USD | 10.64% |
| 2022 Q1 | -15.17 Million USD | -8.42% |
| 2022 FY | -4.64 Million USD | 88.01% |
| 2022 Q4 | -1.4 Million USD | -10.5% |
| 2022 Q3 | -1.26 Million USD | 90.66% |
| 2021 FY | -38.74 Million USD | -52.4% |
| 2021 Q4 | -13.99 Million USD | -233.74% |
| 2021 Q3 | -4.19 Million USD | 62.33% |
| 2021 Q1 | -9.42 Million USD | -39.38% |
| 2021 Q2 | -11.13 Million USD | -18.17% |
| 2020 FY | -25.42 Million USD | -358.38% |
| 2020 Q4 | -6.76 Million USD | 7.07% |
| 2020 Q3 | -7.27 Million USD | -25.72% |
| 2020 Q2 | -5.78 Million USD | -3.23% |
| 2020 Q1 | -5.6 Million USD | 0.0% |
| 2019 FY | 9.84 Million USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| America Great Health | 168.58 Thousand USD | 4306.705% |
| Ampio Pharmaceuticals, Inc. | -250 Thousand USD | -2736.8% |
| Aridis Pharmaceuticals, Inc. | - USD | Infinity% |
| Biora Therapeutics, Inc. | -551 Thousand USD | -1187.114% |
| Bio-Path Holdings, Inc. | -178 Thousand USD | -3884.27% |
| Better Therapeutics, Inc. | -2.72 Million USD | -159.875% |
| Calithera Biosciences, Inc. | -1.38 Million USD | -412.058% |
| Comera Life Sciences Holdings, Inc. | 422.71 Thousand USD | 1777.738% |
| Gene Biotherapeutics, Inc. | - USD | Infinity% |
| eFFECTOR Therapeutics, Inc. | -22.91 Million USD | 69.056% |
| Eloxx Pharmaceuticals, Inc. | - USD | Infinity% |
| Evelo Biosciences, Inc. | - USD | Infinity% |
| Evolutionary Genomics, Inc. | -1.02 Million USD | -594.278% |
| Galera Therapeutics, Inc. | -259 Thousand USD | -2638.224% |
| Innovation1 Biotech Inc. | -52.69 Thousand USD | -13357.816% |
| Kiromic BioPharma, Inc. | -2.79 Million USD | -153.657% |
| Molecular Templates, Inc. | 50.39 Million USD | 114.073% |
| Navidea Biopharmaceuticals, Inc. | -119.29 Thousand USD | -5844.926% |
| NexImmune, Inc. | -1.02 Million USD | -591.921% |
| Orgenesis Inc. | -5.72 Million USD | -23.878% |
| Panbela Therapeutics, Inc. | -25.64 Million USD | 72.348% |
| Point of Care Nano-Technology, Inc. | -4601.00 USD | -154040.404% |
| PaxMedica, Inc. Common Stock | - USD | Infinity% |
| Scopus BioPharma Inc. | - USD | Infinity% |
| Sorrento Therapeutics, Inc. | 29.38 Million USD | 124.133% |
| Statera Biopharma, Inc. | -488.31 Thousand USD | -1352.344% |
| TRACON Pharmaceuticals, Inc. | -232 Thousand USD | -2956.897% |
| Trevena, Inc. | 1.45 Million USD | 587.423% |
| Vaxxinity, Inc. | -2.23 Million USD | -217.457% |
| Vaccinex, Inc. | -16 Million USD | 55.686% |
| Vicapsys Life Sciences, Inc. | - USD | Infinity% |
| Viracta Therapeutics, Inc. | -492 Thousand USD | -1341.463% |
| ZIVO Bioscience, Inc. | 11.61 Thousand USD | 61185.271% |